Biodexa Pharmaceuticals (BDRX) Non-Current Deffered Revenue (2018 - 2025)
Biodexa Pharmaceuticals (BDRX) reported Non-Current Deffered Revenue of $857957.2 for Q4 2025, down 48.82% on a YoY basis from $1.7 million in Q4 2024, and down 29.25% sequentially from $1.2 million in Q2 2025.
Biodexa Pharmaceuticals (BDRX) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 4 years of Non-Current Deffered Revenue data on file, last reported at $857957.2 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 48.82% year-over-year to $857957.2; the trailing twelve-month figure through Dec 2025 stood at $857957.2 (down 48.82% YoY), and the FY2025 full-year result was $850439.2, down 49.27% from the prior year.
- Non-Current Deffered Revenue declined to $857957.2 in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.0 million in Q2 2024 to a low of $857957.2 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | 857,957.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 857,957.20 |
| Jun 30, 2025 | 1.21 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Jun 30, 2019 | -100,332.38 |
| Dec 31, 2018 | -603,493.83 |